Indapamide Versus Hydrochlorothiazide in Elderly Hypertensive Patients With Renal Insufficiency

June 23, 2014 updated by: Xiaoping Chen, West China Hospital

A Comparison of Indapamide SR 1.5 mg With Hydrochlorothiazide 25 mg, in Combination With an ACE-inhibitor, in Old Patients With Mild to Moderate Renal Insufficiency and Hypertension

The purpose of this study is to evaluate the effects of indapamide SR 1.5 mg on renal function, endothelial function, blood pressure variability by comparison with hydrochlorothiazide 25 mg, in patients with Mild to Moderate Renal Insufficiency and Hypertension.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

240

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • Department of Cardiology, West China Hospital, Sichuan University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years to 85 years (OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Creatinine clearance 30 to 90 mL/min/1.73 m2, with variations of less than 20 percent in the 2 weeks before the screening evaluation.
  • Diagnosed hypertension according to guidelines or having taken anti-hypertension drugs.
  • Aged between 65 and 85 years.
  • Willingness to provide written, informed consent.
  • Ability to adhere to study protocol.

Exclusion Criteria:

  • Secondary hypertension.
  • Diabetes mellitus.
  • Atrial flutter/atrial fibrillation.
  • Symptoms of congestive heart failure (NYHA III-IV) or there is evidence that left ventricular EF < 40%.
  • Recent (< 6 months) myocardial infarction or cerebrovascular ischemic symptoms.
  • Recent (< 3 months) or planned coronary revascularization: PCI (percutaneous coronary intervention)/CABG (coronary artery by-pass graft).
  • Severe valvular heart disease.
  • History of hypersensitivity to indapamide, thiazides or to any of the components of the products.
  • Any current condition or other disease known to interfere significantly with the absorption, distribution, metabolism or excretion of study drugs.
  • Participation to another investigational study in the last 3 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Indapamide
Indapamide SR 1.5mg qd
Drug: Indapamide
Indapamide SR 1.5mg qd
ACTIVE_COMPARATOR: Hydrochlorothiazide
Hydrochlorothiazide 25mg qd
Drug: Hydrochlorothiazide
Hydrochlorothiazide 25mg qd

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
renal function
Time Frame: 1 year
Effects of indapamide SR 1.5 mg on renal function by comparison with hydrochlorothiazide 25 mg, in patients with Mild to Moderate Renal Insufficiency and Hypertension.
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
endothelial function
Time Frame: 1 year
Effects of indapamide SR 1.5 mg on endothelial function by comparison with hydrochlorothiazide 25 mg, in patients with Mild to Moderate Renal Insufficiency and Hypertension.
1 year
blood pressure variability
Time Frame: 1 year
Effects of indapamide SR 1.5 mg on blood pressure variability by comparison with hydrochlorothiazide 25 mg, in patients with Mild to Moderate Renal Insufficiency and Hypertension
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

West China Hospital

Investigators

  • Principal Investigator: Xiao P Chen, master, West China Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2010

Primary Completion (ACTUAL)

March 1, 2012

Study Completion (ACTUAL)

December 1, 2013

Study Registration Dates

First Submitted

July 26, 2010

First Submitted That Met QC Criteria

July 28, 2010

First Posted (ESTIMATE)

July 29, 2010

Study Record Updates

Last Update Posted (ESTIMATE)

June 24, 2014

Last Update Submitted That Met QC Criteria

June 23, 2014

Last Verified

June 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • WestChinaH

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe